Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?

The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news